This Micro Cap Is Already Up Big Premarket

By: Dylan Sikes – AllPennyStocks.com News

Wednesday, April 5, 2023

A Boston-based biotech company is already having quite the day on Wednesday leading up to the opening bell after the company announced that it has been awarded the third year of a Fast-Track Small Business Innovation Research grant from the NIH to support the clinical evaluation of TTX-MC138, according to this morning’s press release.

Shares of TransCode Therapeutics Inc. (Nasdaq:RNAZ) are currently being aggressively bid up during Wednesday’s premarket, with traders currently willing to buy shares at $0.422/share (+27.65% implied open for sellers) at the time of writing. This should be an excited session for this micro cap!

TransCode Therapeutics Inc is an RNA oncology company. It is created to defeat the cancer through the intelligent design and effective delivery of RNA therapeutics. The company's lead therapeutic candidate, TTX-MC138, is focused on treating metastatic cancer, which has the potential to produce regression without recurrence in a range of cancers, including breast, pancreatic, ovarian and colon cancer, glioblastomas and others.

Copyright © 2023 AllPennyStocks.com. All rights reserved. Republication or redistribution of AllPennyStocks.com's content is expressly prohibited without the prior written consent of AllPennyStocks.com. AllPennyStocks.com shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.